LevitasBio

LevitasBio is pioneering a novel approach to cell processing with its proprietary Levitation Technology, which uses magnetic fields to separate and analyze cells based on their intrinsic density without labels or harsh mechanical forces. The company's product portfolio, including the LeviCell 96 high-throughput system and LeviSelect kits, targets critical bottlenecks in single-cell genomics, cancer profiling, and cell therapy workflows by improving cell viability, yield, and data quality. As a private, revenue-generating platform company, LevitasBio serves academic, biopharma, and core facility customers, positioning itself as an essential tools provider in the rapidly expanding market for advanced cellular analysis.

Magnetic levitation technology for label-free cell separation and analysis based on intrinsic cell density.

LevitasBio competes with traditional cell separation methods like Fluorescence-Activated Cell Sorting (FACS) and Magnetic-Activated Cell Sorting (MACS), dominated by large companies such as BD Biosciences, Thermo Fisher Scientific, and Miltenyi Biotec. Its differentiation is its label-free, gentle approach that preserves native cell states, targeting a specific niche of sensitive sample processing.